Lakefront Biotherapeutics (LKFT) Operating Expenses (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 12 years of Operating Expenses data on file, last reported at -$74.6 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at -$74.6 million, up 68.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $881.6 million (up 153.53% YoY), and the FY2025 annual result was $706.3 million, up 46.0% from the prior year.
• Operating Expenses declined to -$74.6 million in Q1 2026 per LKFT's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $1.2 billion in Q4 2025 and troughed at -$519.0 million in Q3 2025.
• A 5-year average of $187.6 million and a median of -$74.6 million in 2026 frame the typical range for Operating Expenses.
• On a YoY basis, Operating Expenses climbed as much as 153.03% in 2025 and fell as far as 116.41% in 2025.
• A 5-year view of Operating Expenses shows it stood at $883.9 million in 2022, then dropped by 24.49% to $667.5 million in 2023, then rose by 23.91% to $827.1 million in 2024, then jumped by 49.65% to $1.2 billion in 2025, then tumbled by 106.03% to -$74.6 million in 2026.
• Business Quant data shows LKFT's Operating Expenses at -$74.6 million in Q1 2026, $1.2 billion in Q4 2025, and -$519.0 million in Q3 2025.